Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation
- PMID: 23911680
- DOI: 10.1016/j.urolonc.2013.04.013
Primary care physician PSA screening practices before and after the final U.S. Preventive Services Task Force recommendation
Abstract
Objectives: In May 2012, United States Preventive Services Task Force (USPSTF) finalized its recommendation against prostate-specific antigen (PSA) screening in all men. We aimed to assess trends in PSA screening frequency amongst primary care physicians (PCPs) surrounding the May 2012 USPSTF recommendation.
Methods and materials: The electronic data warehouse was used to identify men aged between 40 and 79 years with no history of prostate cancer or urology visit who were evaluated by an internal medicine or family practice physician between 2007 and 2012. Analyses were directed toward PSA testing within 6-month time period from June to November, with particular focus on the 2011 (pre-USPSTF recommendation) and 2012 (post-USPSTF recommendation) cohorts. The primary outcome measure was proportion of men with at least 1 PSA test during the 6-month pre- and post-USPSTF recommendation periods.
Results: A total of 112,221 men met inclusion criteria. There was a significant decrease in screening frequency between the 2011 and 2012 cohorts (8.6% vs. 7.6%, P = 0.0001; adjusted odds ratio 0.89, 95% confidence interval 0.83-0.95). This decrease was most evident amongst patients aged 40 to 49 years (5.6% vs. 4.6%, P = 0.004) and 70 to 79 years (7.9% vs. 6.2%, P = 0.01). A significant decrease was also observed in patients with highest previous PSA value<1.0 (P<0.0001) and 1.0 to 2.49 ng/ml (P = 0.0074).
Conclusions: Since the USPSTF recommendation was finalized, there is evidence of continuing decreases in PSA testing by PCPs. PCPs may be shifting toward more selective screening practices, as decreases in screening are most pronounced in the youngest and oldest patients and in those with history of PSA values<2.5 ng/ml.
Keywords: Primary care; Prostate-specific antigen; Screening; United States Preventive Services Task Force.
Copyright © 2014 Elsevier Inc. All rights reserved.
Similar articles
-
Impact of the 2012 United States Preventive Services Task Force statement on prostate-specific antigen screening: analysis of urologic and primary care practices.Urology. 2015 Jan;85(1):85-9. doi: 10.1016/j.urology.2014.07.072. Epub 2014 Nov 11. Urology. 2015. PMID: 25440819
-
PSA screening: determinants of primary-care physician practice patterns.Prostate Cancer Prostatic Dis. 2012 Jun;15(2):189-94. doi: 10.1038/pcan.2011.59. Epub 2011 Nov 29. Prostate Cancer Prostatic Dis. 2012. PMID: 22343837
-
Prostate-specific antigen testing: men's responses to 2012 recommendation against screening.Am J Prev Med. 2013 Aug;45(2):182-9. doi: 10.1016/j.amepre.2013.04.005. Am J Prev Med. 2013. PMID: 23867025
-
The effect of the USPSTF PSA screening recommendation on prostate cancer incidence patterns in the USA.Nat Rev Urol. 2017 Jan;14(1):26-37. doi: 10.1038/nrurol.2016.251. Epub 2016 Dec 20. Nat Rev Urol. 2017. PMID: 27995937 Free PMC article. Review.
-
Impact of the United States Preventive Services Task Force 'D' recommendation on prostate cancer screening and staging.Curr Opin Urol. 2017 May;27(3):205-209. doi: 10.1097/MOU.0000000000000383. Curr Opin Urol. 2017. PMID: 28221220 Review.
Cited by
-
Racial, ethnic, and socioeconomic disparities in rates of stage IV prostate cancer after USPSTF category "D" recommendation against prostate-specific antigen screening: a retrospective cohort study.Transl Androl Urol. 2024 Jul 31;13(7):1093-1103. doi: 10.21037/tau-24-90. Epub 2024 Jul 16. Transl Androl Urol. 2024. PMID: 39100847 Free PMC article.
-
Incidence trends and survival of metastatic prostate cancer with bone and visceral involvement: 2010-2019 surveillance, epidemiology, and end results.Front Oncol. 2023 Aug 3;13:1201753. doi: 10.3389/fonc.2023.1201753. eCollection 2023. Front Oncol. 2023. PMID: 37601697 Free PMC article.
-
Retrospective analysis to describe trends in first-ever prostate-specific antigen (PSA) testing for primary healthcare facilities in the Gauteng Province, South Africa, between 2006 and 2016.BMJ Open. 2022 Mar 21;12(3):e050646. doi: 10.1136/bmjopen-2021-050646. BMJ Open. 2022. PMID: 35314469 Free PMC article.
-
Trends in Incidence of Metastatic Prostate Cancer in the US.JAMA Netw Open. 2022 Mar 1;5(3):e222246. doi: 10.1001/jamanetworkopen.2022.2246. JAMA Netw Open. 2022. PMID: 35285916 Free PMC article.
-
Geospatial analysis, web-based mapping and determinants of prostate cancer incidence in Georgia counties: evidence from the 2012-2016 SEER data.BMC Cancer. 2021 May 6;21(1):508. doi: 10.1186/s12885-021-08254-0. BMC Cancer. 2021. PMID: 33957887 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous
